Morning-After Pill = Morning After Stock Spike?

| About: Barr Pharmaceuticals (BRL)
This article is now exclusive for PRO subscribers.

Excerpt from our One Page Annotated Wall Street Journal Summary (receive it by email every morning by signing up here):

FDA Moves Toward Approving Over-the-Counter Plan B Sales

  • Summary: The FDA yesterday sent a letter to Barr Parmaceuticals announcing that it plans to allow women to purchase the emergency contraceptive Plan B without a prescription. The FDA's acting commissioner, Dr Andrew von Eschenbach, is set to appear before a Senate confirmation hearing. Two Democratic members of the committee said that they still planned to block his nomination because he had failed to provide a clear positive decision to allow Plan B without a prescription. The FDA letter said that Barr would need to ammend its application to focus on women aged 18 and older rather than 16 and older, but was signed by Dr Eschenbach himself.
  • Comment on related stocks/ETFs: Incremental positive for Barr Pharmaceuticals Inc. (BRL).